As of February 6, 2026, the technology sector is witnessing a paradoxical shift in the mergers and acquisitions (M&A) landscape. While the sheer number of transactions has hit an eight-year plateau, the total capital being deployed is reaching historic highs. This "K-shaped" recovery in deal-making is almost entirely driven
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 3% above analysts’ estimates. Its non-GAAP profit of $1.35 per share was 8.3% above analysts’ consensus estimates.
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $1.35 per share was 8.3% above analysts’ consensus estimates.
Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging frontiers of cell and gene therapy (CGT), the ability to store, manage, and analyze biological samples with absolute precision is no longer a luxury—it [...]
In a definitive display of market resilience, the S&P 500 (CME:GSPC) achieved a landmark milestone in May 2024, crossing the 5,300 threshold for the first time in history. This surge, culminating in a record close of 5,308.18 on May 15, 2024, represented a fundamental shift
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and its peers.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that blew past Wall Street expectations. The report highlighted a dramatic acceleration in the adoption of its clonoSEQ diagnostic test, positioning the company as a
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion "co-innovation" partnership at the J.P. Morgan Healthcare Conference on January 12, 2026. This five-year strategic alliance aims to re-engineer the
LAS VEGAS — In a landmark keynote that has redefined the trajectory of high-performance computing, Advanced Micro Devices, Inc. (NASDAQ:AMD) Chair and CEO Dr. Lisa Su took the stage at CES 2026 to announce the company’s transition into the "yotta-scale" era of artificial intelligence. Centered on the full reveal of the Instinct MI400 series and [...]
In a landmark achievement for computational medicine, researchers at Harvard Medical School have developed a "generalist" artificial intelligence model that is fundamentally reshaping the landscape of oncology. Known as the Clinical Histopathology Imaging Evaluation Foundation (CHIEF), this AI system has demonstrated a staggering 98% accuracy in diagnosing rare and metastatic cancers, while simultaneously predicting patient [...]
The first full trading week of 2026 has opened with a seismic shift in both the geopolitical landscape and the financial markets. Following the dramatic "weekend capture" of Venezuelan President Nicolás Maduro by U.S. special operations forces, Wall Street responded with a powerful "relief rally" on Monday, January 5,
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
ILLUMINA INC (ILMN) shows a strong technical breakout setup with a high trend rating and a defined bull flag pattern, suggesting a potential entry point for momentum traders.
